Ophthalmology Times

Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Fierce Biotech

Ollin eyes phase 3 after bispecific tops Vabysmo in early-stage trial, clearing more retinal disease faster

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
Healio

FDA approves Eylea HD for macular edema after retinal vein occlusion

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
Managed Healthcare Executive

Novel sustained-release DME therapy shows promising results

A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...

Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) i…

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
Medscape

Fluocinolone Implant Slows Diabetic Retinopathy in Patients With Macular Edema

Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...
Medscape

FDA Approves Ranibizumab for Diabetic Macular Edema

August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...